alexa New & Emerging Drugs for Squamous Cell Lung Cancer | Abstract
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication Open Access


Lung Cancer is the leading cause of cancer-related death worldwide. Squamous cell lung cancer (SQCLC) is the second most common histology (20-30% of cases) among non-small cell lung cancers (NSCLC), yet the treatment options remain limited [1]. The current standard for first line treatment of advanced or metastatic SQCLC consists of mainly platinum based chemotherapy. Recently, necitumumab in combination with platinum based doublet therapy was approved as front-line therapy. Second line options until recently included docetaxel, gemcitabine, nab-paclitaxel and erlotinib. Now newer agents including afatinib, ramucirumab/docetaxel, nivolumab and pembrolizumab are also available with superior clinical benefits

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Janaki Sharma and Haiying Cheng


Lung Cancer,non-small cell lung cancers,chemotherapy,front-line therapy, Lung Cancer,non-small cell lung cancers,chemotherapy,front-line therapy

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version